Crossmark

Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-020-04895-x

Published Online: 2020-11-23

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kotecha, Rupesh http://orcid.org/0000-0001-6927-0402
Schiro, Brian J.

Sporrer, Justin

Rubens, Muni

Appel, Haley R.

Calienes, Kathleen S.

Boulanger, Belinda

Pujol, Marietsy V.

Suarez, Deborah T.

Pena, Ashley

Kudryashev, Alex

Mehta, Minesh P.
License Information

Text and Data Mining valid from 2020-11-23

Version of Record valid from 2020-11-23
More Information

Article History

Received: 15 May 2020

Accepted: 12 November 2020

First Online: 23 November 2020

Ethics approval and consent to participate

: WIRB approval (Study Number 1281424) on April 19, 2020. Written, informed consent to participate will be obtained from all participants.

: Willing to provide a model consent form on request.

: R. Kotecha: Honorarium from Elsevier, Elekta AB, Accuray Inc., Novocure Inc.; speaker’s bureau for Novocure Inc.; research support from Novocure Inc. and Medtronic Inc. (for this study).B.J. Schiro: Speaker’s bureau for Penumbra, Philips, and Sirtex; research support from Medtronic Inc. (for this study).J. Sporrer: None.H.R. Appel: None.<i>M. Rubens</i>: None.K.S. Calienes: None.B. Boulanger: None.M.V. Pujol: None.D.T. Suarez: None.A. Pena: None.A. Kudryashev: None.M.P. Mehta: Consulting for Karyopharm, Tocagen, Astra-Zeneca, Blue Earth Diagnostics, Celgene, Abbvie; Board of Directors: Oncoceutics.

Document is current

Any future updates will be listed below